October 21, 2020 — According to an article in ARRS' American Journal of Roentgenology (AJR), secondary interpretations of body magnetic resonance imaging (MRI) at tertiary care centers identify a high rate of discrepancies — with primary errors being interpretive in origin — suggesting that subspecialty interpretations should be encouraged, and institutions should provide adequate resources for these interpretations to occur

October 21, 2020 — The BBC News reported that Luke Allard of Mill Houses, King's Lynn, died at Queen Elizabeth Hospital in March one day after being discharged. Allard, 28, had Marfan syndrome, a genetic disorder that can cause heart issues.

Transitioning to a new device vendor can provide improvements to outdated technology and workflow. It also requires a commitment to onboarding and training the technologists to properly operate any new device.

October 20, 2020 — A new multi-institutional study published in the journal Radiology identifies patterns in abnormal brain magnetic resonance imaging (MRI) findings in patients with COVID-19.

October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnose, treat, and monitor disease.

October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.

October 19, 2020 — Volpara Solutions, a leader in AI-powered breast density assessment, announced that it has changed the company's name to Volpara Health. A purpose-driven software company on a mission to prevent advanced-stage breast cancer, Volpara Health is undergoing an extensive rebranding to better represent its commitment to helping save families from cancer.

October 19, 2020 — Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase inhibitors and immune checkpoint inhibitors.

October 19, 2020 — Carestream recognizes the impact of artificial intelligence in radiology applications, and continuously develops AI-based solutions to provide clinician, patient and business benefits.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now